Proffesor . W E Carsten

Biography

Dr Carsten Reinhardt joined Immatics Biotechnologies GmbH in October 2009 from Micromet, Inc. (Bethesda, MD), where he was Chief Medical Officer and a member of the management board. Previously, as International Medical Leader at Hoffmann-La Roche (Basel, Switzerland), Dr Reinhardt had global responsibility for the development of Herceptin®. Prior to his tenure at Roche, Dr Reinhardt was Head of Clinical Development at Fresenius Biotech (Munich, Germany). Dr Reinhardt has extensive experience in translational development as well as in early and late-stage clinical trial design. Under his leadership multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe. This included the set-up and oversight of pivotal trials leading to the approval of various anti-cancer drugs including Blincyto® in acute lymphoblastic leukemia (ALL), Removab® in solid tumors as well as various sBLA/MAA for Herceptin® in additional indications such as adjuvant breast cancer and gastric cancer. Prior to joining the pharma and biotech industry, Dr Reinhardt held various academic medical positions and worked at the University of Tuebingen and Max Planck Institute, Munich to complete his curriculum in Neurology. Dr Reinhardt has co-authored more than 40 publications in peer-reviewed journals including Science, Nature Medicine, Lancet, Journal of Clinical Oncology, Cancer Research, and Journal of Experimental Medicine. Dr Reinhardt received a Medical Degree in 1994 from the University of Munich, Germany and, in addition, completed a Ph.D. thesis in Cellular Immunology at the Institute of Immunology in Munich, Germany (summa cum laude). He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the Association for Cancer Immunotherapy as well as of the European Society of Medical Oncology, and is Visiting Professor for Pharmaceutical Medicine at the University of Basel.    

Research Interest

 multiple biological compounds that address oncology and immunology diseases were progressed from early preclinical development through first-in-man studies towards approvals in the US and Europe. This included the set-up and oversight of pivotal trials leading to the approval of various anti-cancer drugs including Blincyto® in acute lymphoblastic leukemia